[Hepatorenal syndrome. Clinical and pathogenetic aspects and therapeutic approach].
D004088:Dihydroergotoxine / Q000627:therapeutic use; D004298:Dopamine / Q000627:therapeutic use; D004731:Endotoxins / Q000097:blood; D005665:Furosemide / Q000627:therapeutic use; D006439:Hemodynamics; D006801:Humans; D007674:Kidney Diseases / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D008103:Liver Cirrhosis / Q000150:complications* / Q000503:physiopathology; D018377:Neurotransmitter Agents / Q000502:physiology; D010646:Phentolamine / Q000627:therapeutic use; D011311:Pressoreceptors / Q000503:physiopathology; D011379:Prognosis; D011453:Prostaglandins / Q000097:blood; D012079:Renal Circulation; D012084:Renin-Angiotensin System; D013577:Syndrome
D004731:Endotoxins; D018377:Neurotransmitter Agents; D011453:Prostaglandins; D004088:Dihydroergotoxine; D005665:Furosemide; D004298:Dopamine; D010646:Phentolamine
La sindrome epato-renale. Aspetti clinici, patogenetici ed indirizzi di trattamento.